Regeneron Pharmaceuticals
A leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $2.0m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 89 % | (24 %) | 8 % | 8 % | (2 %) | 4 % | 10 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 58 % | 42 % | 39 % | 37 % | 36 % | 39 % | 39 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 50 % | 36 % | 30 % | 31 % | 26 % | 25 % | 27 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 18 % | 30 % | 34 % | 36 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Regeneron Pharmaceuticals is a prominent biotechnology company that has been at the forefront of medical innovation for over 35 years. The company specializes in developing life-transforming medicines for individuals suffering from serious diseases. Regeneron operates in the biopharmaceutical market, focusing on research, development, and commercialization of treatments for conditions such as cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases.
Regeneron's business model is centered around leveraging its proprietary technologies and extensive research capabilities to discover and develop new therapies. The company collaborates with various academic and research institutions, as well as other pharmaceutical companies, to enhance its research and development efforts. These collaborations help Regeneron to stay at the cutting edge of scientific and technological advancements.
The company generates revenue primarily through the sale of its approved medicines. Additionally, Regeneron earns income from licensing its technologies and entering into strategic partnerships. These partnerships often involve co-development and co-commercialization agreements, which allow Regeneron to share both the costs and profits associated with bringing new treatments to market.
Regeneron's clients include healthcare providers, hospitals, and clinics that administer its medicines to patients. The company also works closely with regulatory agencies to ensure that its products meet stringent safety and efficacy standards.
In summary, Regeneron Pharmaceuticals is a leader in the biotechnology sector, dedicated to developing innovative treatments for serious diseases. The company’s success is driven by its strong research and development capabilities, strategic partnerships, and commitment to improving patient outcomes.
Keywords: biotechnology, life-transforming medicines, serious diseases, research, development, collaborations, proprietary technologies, revenue, healthcare providers, regulatory agencies.
Tech stack
Investments by Regeneron Pharmaceuticals
Edit
